Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-07-19
2011-07-19
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S154100, C435S069600, C435S328000, C435S343200, C530S387300, C530S388100, C530S388750, C530S388800
Reexamination Certificate
active
07981416
ABSTRACT:
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5658741 (1997-08-01), Bolton et al.
patent: 5897862 (1999-04-01), Hardy et al.
patent: 6074635 (2000-06-01), Abrignani
patent: 6294654 (2001-09-01), Bogen et al.
patent: WO 91/99967 (1991-07-01), None
patent: WO 00/58363 (2000-10-01), None
patent: WO 03/033644 (2003-04-01), None
Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,” Methods: a companion to Methods in Enzymology, 8: 83-93 (1995).
Bruccoleri et al., “Prediction of the folding of short polypeptide segments by uniform conformational sampling,” Biopolymers, 26: 137-168 (1987).
Carter et al., “High levelEscherichia coliexpression and production of bivalent humanized antibody fragment,” Bio/Technology, 10: 163-167 (1992).
Casset et al., Biochemical and Biophysical Research Communications, 307:198-205 (2003).
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 196: 901-917 (1987).
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, 342(6252): 877-883 (1989).
Chothia et al., “Structural repertoire of the human VHsegments,” J. Mol. Biol., 227: 799-817 (1992).
Colman, Research in Immunology, 145:33-36, 1994.
Fang et al., “Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VHgene segment usage and preferential usage of VλIIIb,” The Journal of Experimental Medicine, 179: 1445-1456 (1994).
Foote et al., “Antibody framework residues affecting the conformation of the hypervariable loops,” J. Mol. Biol., 224: 487-499 (1992).
Hardy et al., “A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice,” Cancer Research 54: 5793-5796 (1994).
Hardy et al., “A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice,” Proc. Natl. Acad. Sci. USA, 94: 5756-5760 (1997).
Hardy et al., “Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: A comparative study,” Human Antibodies, 8(2): 95-98 (1997).
Hardy et al., “A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes,” Cellular Immunology, 118: 22-29 (1989).
Hardy et al., “Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma,” International Journal of Oncology, 19: 897-902 (2001).
Kettleborough et al., “Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction,” European Journal of Immunology, 23(1): 206-211 (1993).
MacCallum et al., J. Mol. Biol., 262: 732-745 (1996).
Marks et al., “My-passing immunization human antibodies from V-gene libraries displayed on phage,” J. Mol. Biol., 222: 581-597 (1991).
Martin et al., “Structural families in loops of homologous proteins: automatic classification, modeling and application to antibodies,” J. Mol. Biol., 263: 800-815 (1996).
Paul, Fundamental Immunology, 3rd Edition, pp. 292-295 (1993).
Raiter et al., International Immunology, 12(11):1623-1628 (2000).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79: 1979-1983 (1982).
Stemmer et al., “Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides,” Gene, 164: 49-53 (1995).
Tramontano et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VHdomains of immunoglobulins,” J. Mol. Biol., 315: 175-182 (1990).
Hardy Britta
Jones Steven Tarran
Klapper Leah
Blanchard David J.
CureTech Ltd.
Mor-Research Applications Ltd.
Winston & Strawn LLP
LandOfFree
Humanized immunomodulatory monoclonal antibodies for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized immunomodulatory monoclonal antibodies for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunomodulatory monoclonal antibodies for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712698